T he battle between weight-loss drugs continues. While studies show semaglutide (sold under the brand names Ozempic and ...

The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Glucagon-like peptide-1 receptor agonists improve cardiovascular outcomes and reduce mortality in patients with type 2 ...

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

A decision is expected in the fourth quarter of 2025.

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and prevention ...

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

A major clinical trial reveals Wegovy a popular weight loss drug also treats serious liver disease MASH—reducing liver inflammation and scarring in most patients ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE ...